Treatment‐emergent adverse events in dupilumab‐treated patients with allergic diseases: A meta‐analysis
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81970859, 81670913)
This publication has 8 references indexed in Scilit:
- Cutaneous barrier dysfunction in allergic diseasesJournal of Allergy and Clinical Immunology, 2020
- Dupilumab: A Review in Chronic Rhinosinusitis with Nasal PolypsDrugs, 2020
- Dupilumab to Treat Type 2 Inflammatory Diseases in Children and AdolescentsPediatric Drugs, 2020
- Dupilumab: A New Paradigm for the Treatment of Allergic DiseasesJournal of Investigational Allergology and Clinical Immunology, 2018
- ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patientsJournal of the European Academy of Dermatology and Venereology, 2016
- Strategies targeting the IL-4/IL-13 axes in diseaseCytokine, 2015
- Immune modulation for treatment of allergic diseaseImmunological Reviews, 2011
- Burden of allergic disease in the UK: secondary analyses of national databasesClinical & Experimental Allergy, 2004